2012

Bacterial translocation in cirrhotic patients: relationship with renal insufficiency and prognosis

IDIBELL Seminars. June 15, 2012. At the conference Dr José Such, from the Liver Unit of the General University Hospital of Alicante and CIBERehd, and specialized in bacterial translocation in cirrhotic patients, spoke of translocation and clinical effects. “The cirrhosis causes portal hypertension, which can lead to splanchnic vasodilation, all of which can cause the […]

Bacterial translocation in cirrhotic patients: relationship with renal insufficiency and prognosis Read More »

Bellvitge researchers develop new method to reduce length of stay for patients with pneumonia

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) have found a new safe and effective method to reduce the duration of intravenous antibiotic therapy and the length of hospital stay for patients with community-acquired pneumonia. This strategy would help to optimize the care of hospitalized patients with pneumonia and reduce the hospital costs. In Europe,

Bellvitge researchers develop new method to reduce length of stay for patients with pneumonia Read More »

The Clinical Research Ethics Committee of Bellvitge announces its work

The Clinical Research Ethics Committee (CEIC) of the Bellvitge University Hospital was held on June 11th of an extraordinary session addressed to professionals interested in biomedical research, including basic and clinical researchers with the aim of introducing their work and exploring new avenues of communication with the scientific community.

The Clinical Research Ethics Committee of Bellvitge announces its work Read More »

The IDIBELL among the finest research institutions in Spain

The IDIBELL ranks fifth in a ranking of research institutions in Spain in a study published this week by the Fundación Conocimiento y Desarrollo (Knowledge and Development Foundation). Furthermore, the Catalan Institute of Oncology from Hospitalet, partner of IDIBELL, ranks second and, among universities, UB appears in first position. This study collects data from scientific

The IDIBELL among the finest research institutions in Spain Read More »

The epigenome of newborns and centenarians is different

An international study coordinated by Manel Esteller check how epigenetic marks are degrading over time. Since epigenetic lesions are reversible, it would be possible to develop drugs that increase the life span What happens in our cells after one hundred years? What is the difference at the molecular level between a newborn and a centenary?

The epigenome of newborns and centenarians is different Read More »

Walk On Project” funds an IDIBELL project with almost 100,000 euros

The Walk on Project (WOP) nonprofit foundation, in collaboration with BBK Fundazioa, will fund with 98,000 euros a research project led by Dr. Aurora Pujol, ICREA research professor in Bellvitge Institute for Biomedical Research (IDIBELL), who is an expert in Human Genetics and Neurodegenerative Diseases. The project, entitled “Pharmacological strategies for the regeneration of myelin

Walk On Project” funds an IDIBELL project with almost 100,000 euros Read More »

Alfredo García, new Director of Bellvitge Hospital

Dr. Alfredo Garcia Diaz has been appointed managing director of the Bellvitge University Hospital and managing director of the South Metropolitan Territorial Management of the Catalan Institute of Health. Replaced in this role Dr. Xavier Corbella, who has been appointed manager of the Hospital Santa Creu i Sant Pau in Barcelona.

Alfredo García, new Director of Bellvitge Hospital Read More »

Study of 14-3-3 proteins in chemotherapy resistance

Certain proteins, such as 14-3-3, conserve their basic functions of cell cycle control in diverse organisms, from worms to humans. In a study led by Julián Cerón and Simó Schwartz Jr, researchers from the Bellvitge Biomedical Research Institute (IDIBELL) and the Research Institute of Vall d’Hebron (VHIR) respectively, have described germ line functions of par-5,

Study of 14-3-3 proteins in chemotherapy resistance Read More »

IDIBELL project, funded by EMBO

Dr. Antonio Gentilella has get an EMBO Long-Term Fellowship The project, leaded by Dr. Antonio Gentilella and funded by an EMBO Long-Term Fellowship, is focussed on understanding the mechanisms by which the tumor suppressor p53, also known as the guardian of genome, is activated in response to ribosomal impairment, a cause of two rare anemias,

IDIBELL project, funded by EMBO Read More »

Identified an anti-oncogene into an oncogene

A study led by Manel Esteller has discovered the existence of an antitumor molecule that has been originated within an oncogene. A common point in all human tumors is that they produce an activation of oncogenes, genes that cause cancer and they also cause a loss of function of the protective genes, called anti-oncogenes or

Identified an anti-oncogene into an oncogene Read More »

Scroll to Top